Replies to post #106546 on Biotech Values

[DewDiligence]

Thanks, Rockrat. Daiichi Sankyo’s Edoxaban (DU-176b) has its own section in the “What’s New in the Anticoagulant Market?” compilation in #msg-55640904. Regards, Dew

p.s. The above compilation is accessible from the MNTA ReadMeFirst, but the version referenced there is not always up to date. To access the latest version, please use the link in the iBox of the Biotech Values board.

[DewDiligence]

Regado presents PK/PD data on REG1 Factor-IX inhibitor at AHA (FWIW):

http://finance.yahoo.com/news/Regado-Biosciences-Inc-prnews-1805950825.html?x=0&.v=2

[DewDiligence]

Regado presents final phase-2b results for REG1 at ACC this weekend:

http://finance.yahoo.com/news/Regado-Biosciences-Inc-prnews-2821788812.html?x=0&.v=1

FWIW

[DewDiligence]

Regado provides additional phase-2b data on RB006/RB007 anticoagulant and reversing agent:

http://finance.yahoo.com/news/Regado-Biosciences-Inc-prnews-3336913480.html?x=0&.v=1

The main results from this phase-2b trial were presented at ACC in Mar 2011 (#msg-61433660).